WHO WE ARE
We are a pre-clinical company focused on discovery and development of autophagy targeted therapeutics primarily for cancer treatment, as well as other disease indications.
Numerous pre‐clinical studies have now shown a requirement for autophagy in sustaining tumor growth, as well as in providing a mechanism of resistance to a number of currently used therapies.
Our Partners
What We Do
Research has shown inhibition of autophagy can dramatically impact tumor growth in pre‐clinical models.
There is a need for potent and specific autophagy inhibitors to advance these important findings into clinical practice.